Lagerstandorte
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Vorbehaltlich Verfügbarkeit
Dokumentation
Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.
26889-93-0Amoxicillin EP Impurity B
● Auf Lager
| Katalog-Nr.:: | VL1970003 |
|---|---|
| CAS-Nr.:: | 26889-93-0 |
| Summenformel:: | C16H19N3O5S |
| Molare Masse:: | 365.40 g/mol |
Zusätzliche Informationen zu CAS 26889-93-0
Parent drug
AmoxicillinIUPAC-Name
(2S,5R,6R)-6-[[(2S)-2-Amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acidPharmakopöe-Synonyme
Amoxicillin Related Compound B; L-AmoxicillinOther Synonyms
N/ASmile
O=C([C@@H](C(C)(C)S[C@]1([H])[C@@H]2NC([C@@H](N)C3=CC=C(O)C=C3)=O)N1C2=O)OInChI
InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10+,11-,14+/m0/s1Beschreibung
Amoxicillin EP Impurity B also known as Amoxicillin Related Compound B ; L-Amoxicillin, in various pharmacopoeias, is a highly characterized standard. It meets strict regulatory requirements set by USP, EMA, JP, and BP, making it a crucial component in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Amoxicillin. Amoxicillin EP Impurity B (CAS No: 26889-93-0) or Amoxicillin Related Compound B is an impurity formed in Amoxicillin, which is a popular antimicrobial medicine that has a prominent role in the therapy of various infections, particularly those of the respiratory tract.
References
Valvo, L., et al. Development of a Simple Liquid Chromatographic Method with UV and Mass Spectrometric Detection for the Separation of Substances Related to Amoxicillin Sodium.†Journal of Chromatography A, vol. 797, no. 1-2, Feb. 1998, pp. 311–16, https://doi.org/10.1016/s0021-9673(97)00952-7 Zhu, Yongxin, et al. Evaluation of Liquid Chromatography Methods for the Separation of Ampicillin and Its Related Substances.†Journal of Pharmaceutical and Biomedical Analysis, vol. 14, no. 5, Mar. 1996Angebot anfordern
„*“ zeigt erforderliche Felder an
